Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
11.76% $1.520
America/New_York / 14 sep 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 49.33 mill |
EPS: | -0.630 |
P/E: | -2.41 |
Earnings Date: | Aug 18, 2023 |
SharesOutstanding: | 32.45 mill |
Avg Daily Volume: | 1.020 mill |
RATING 2023-10-13 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.41 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.05x |
Company: PE -2.41 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.166 - 1.454 ( +/- 10.99%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-29 | Gulyas John | Buy | 3 000 | Common stock |
2023-12-28 | Gulyas John | Buy | 2 500 | Common stock |
2023-12-28 | Gulyas John | Buy | 2 500 | Common stock |
2023-09-01 | Boon Jarrett Adam | Buy | 0 | Common Stock |
2023-08-31 | Gulyas John | Buy | 1 666 666 | Common stock |
INSIDER POWER |
---|
98.79 |
Last 89 transactions |
Buy: 11 303 898 | Sell: 784 416 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.520 (11.76% ) |
Volume | 1.970 mill |
Avg. Vol. | 1.020 mill |
% of Avg. Vol | 193.12 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.